Similar tags:
Dr. Geoffrey Oxnard on Managing Acquired Resistance to EGFR Inhibitor Therapy (and Probably Crizotinib, Too)
Dr. David Spigel: What are the most promising targeted therapy approaches in lung cancer for the next few years?
Dr. Monty Pal on Leading Options for First Line Treatment of Advanced Kidney Cancer
Dr. Heather Wakelee on the Most Promising New Agents and Pathways for Treating Lung Cancer in the Coming Years
Dr. Ravi Salgia: How Do I Discuss the Side Effects of Targeted Therapies, as Compared with Chemotherapy?
Dr. Ravi Salgia on Management Strategies for Acquired Resistance to Targeted Therapies, Single Focus or More Diffuse
Dr. Greg Riely: How Should We Approach Acquired Resistance to Targeted Therapies in Advanced NSCLC?
GRACE, cancerGRACE, GRACEcast, advanced NSCLC, Rosalyn Juergens, McMaster University, molecular oncology, targeted therapy, NSCLC histology,
Dr. Greg Riely: How I Use Molecular Marker Information in Earlier Stage NSCLC Patients
ASCO Lung Cancer Highlights, Part 13: The Immune Checkpoint Inhibitor MPDL3280A in Advanced NSCLC (audio)
Highlights in Lung Cancer, 2013: MEK Inhibitors for KRAS Mutation-Positive NSCLC (audio)
Highlights in Lung Cancer, 2013: MEK Inhibitors for KRAS Mutation-Positive NSCLC (video)
Dr. Geoffrey Oxnard on What Molecular Markers to Test for in Advanced NSCLC, and in Whom?
Dr. Phil Bonomi, How Do I Discuss the Side Effects of Targeted Therapies, as Compared with Chemotherapy?
ASCO Lung Cancer Highlights, Part 11: Nintedanib with Second Line Chemotherapy for Advanced NSCLC (audio)
ASCO Lung Cancer Highlights, Part 11: Nintedanib with Second Line Chemotherapy for Advanced NSCLC (video)
ASCO Lung Cancer Highlights, Part 12: Ganetespib with Second Line Chemotherapy for Advanced NSCLC (video)
ASCO Lung Cancer Highlights, Part 12: Ganetespib with Second Line Chemotherapy for Advanced NSCLC (audio)
ASCO Lung Cancer Highlights, Part 13: The Immune Checkpoint Inhibitor MPDL3280A in Advanced NSCLC (video)
What Are Heat Shock Protein (HSP) 90 Inhibitors and How May They Help Fight Lung Cancer?
Treating Newly Diagnosed Kidney Cancer
Immunotherapy Combinations: Best Balance of Activity and Tolerability?
Small Cell Lung Cancer Patients Can Benefit from Immunotherapy
Should PD-L1 be Used as a Biomarker for Immunotherapy in Lung Cancer?
Immunotherapy for Previously Treated Advanced Non-Small Cell Lung Cancer
Immunotherapy for Lung Cancer: General Concepts
Immunotherapy Combinations: Is this the Future for Treating Lung Cancer?
Time to Response to Immunotherapy and the Concept of Pseudoprogression
Can or Will Specific Molecular Characteristics Help Determine Which ALK Inhibitor to Choose?
Are There Clinically Significant Differences Among the Second Generation ALK Inhibitors?
Do You Order PD-L1 Testing Before Choosing an Immune Checkpoint Inhibitor?
What is the Optimal Duration of Immunotherapy?
Should PD-L1 Testing Be Ordered at Diagnosis or After Progression?
Immunotherapy for First Line Therapy of Advanced NSCLC
ROS-1 Rearrangements: What Are They?
Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements
Timing of Second Generation ALK Inhibitors: First Line vs. Treatment after Acquired Resistance
Promising Early Data for Oral Inhibitor Buparlisib
Immunotherapy as First-Line Treatment
Ceritinib and Other Second Generation ALK Inhibitors for Acquired Resistance in ALK-Positive NSCLC
Immunotherapy Combinations
ALK Rearrangements: What Are They, and Who Has Them?
Master The NEC - Anti-Oxidant Inhibitors at terminations - Yes, No, Maybe for Electricians
Case Based Panel Discussion 2.2 Patient with Asymptomatic Brain Metastases -Focal Radiation Before Alk Inhibitor or Begin with ALK Inhibitor
How does Checkpoint Inhibitor Therapy Work when there’s no Checkpoint Expressed on a Patient's Cancer
AKT inhibitor
TWiP 116: One drug to rule them all
TWiM #71: Colon cancer’s little shop of horrors
TWiP 66: A nitrile warhead for Chagas disease
Discover more
Search
